학술논문

Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal.
Document Type
Article
Source
Indian Journal of Medical & Paediatric Oncology. Jul-Sep2015, Vol. 36 Issue 3, p172-175. 4p.
Subject
*CANCER chemotherapy
*EAR canal
*ADJUVANT treatment of cancer
*DOCETAXEL
*CISPLATIN
*PACLITAXEL
*FLUOROURACIL
*MAGNETIC resonance imaging
*CANCER
Language
ISSN
0971-5851
Abstract
Background: Carcinoma of external auditory canal (EAC) is a very rare malignancy with surgical resection as the main modality of treatment. The outcomes with nonsurgical modalities are very dismal. We present a retrospective analysis of 4 patients evaluating the role of neoadjuvant chemotherapy in technically unresectable cancers. Materials and Methods:This is a retrospective analysis of 4 patients from our institute from 2010 to 2014 with carcinoma EAC who were deemed unfi t for surgery due to extensive disease involving occipital bone with soft tissue infi ltration (n = 2), temporal dura (n = 1), left temporal lobe, and extensive soft tissue involvement (n = 1). All these patients received neoadjuvant chemotherapy with docetaxel, cisplatin and 5 fl uorouracil (n = 3) and paclitaxel and cisplatin (n = 1). Results: Response evaluation showed a partial response (PR) in 3 and stable disease (SD) in 1 patient by Response Evaluation Criteria in Solid Tumors criteria. All 3 patients who received 3 drug chemotherapy had PR while 1 patient who received 2 drug chemotherapy had SD. Two of these patients underwent surgery, and other 2 underwent defi nitive chemoradiation. One of 3 patients who achieved PR underwent surgical resection; the other 2 remained unresectable in view of the persistent intradural extension and infratemporal fossa involvement. One patient who had SD could undergo surgery in view of clearance of infraatemporal fossa. Recent follow-up shows that 3 out of these 4 patients are alive. Conclusion: This indicates that there may be a role of induction chemotherapy in converting potentially unresectable tumors to resectable disease that could produce better outcomes in carcinoma EAC. [ABSTRACT FROM AUTHOR]